Investor Presentaiton
IBI-322 (PD-L1/CD47) Development Plan Overview
Global First-in-class PD-L1/CD47 Bispecific Antibody at Clinical Stage
•
IBI-322 Differentiated Advantages
Manageable safety profiles with reduced CD47 binding on RBC to
mitigate anemia AE and decreased RBC phagocytosis due to weak
CD47 blockade activity
Improved DMPK profiles with reduced peripheral CD47 mediated sink
effect and Optimized biodistribution and enhanced PD-L1+ tumor
uptake
Clinical Highlights
Modified Fibonacci method was used in the dose escalation design of
all studies at present for the ongoing Phase 1 trial.
•
DLT were not observed in all dose groups
•
Incidence and degree of anemia were low.
Preliminary antitumor activity has been observed.
CD47/PDL1
CD47"
PDL1*
Pre-clinical Highlights
89 Zr
20
0
%ID/g
89Zr-DFO#
1. CD47+, PD-L1+ tumor cells were
subcutaneously implanted in MC38
tumor-bearing mice with CD47
knock-in
2. 89Zr-labeled IBI322, anti-CD47 mAb
and anti-PD-L1 mAb were
administrated intravenously at
0.5mg/kg
After 24h of scanning, IBI322 was found to be highly distributed in CD47+ PD-L1+
subcutaneous tumor tissues, which proved IBI322 had a strong targeting ability
IBI-322 Development Program Overview
•
China
Clinical
progress
US
Enrolling patients in the Phase 1a/1b studies for advanced
malignancies
Started patient enrolment in Phase 1a in advanced
malignancies in 2021.02
2021 plan
•
Plan to enter Phase 1b trial in China and get preliminary PoC data
Innovent
First clinical stage PD-L1/CD47 bispecific under global development; Phase 1 trials ongoing in China and US.
Preliminary promising tolerability, safety and anti-tumor activity observed.
Confidential
Copyright©2021 Innovent Biologics
29
29View entire presentation